共 151 条
[1]
Melmed S(2009)Guidelines for acromegaly management: an update J Clin Endocrinol Metab 94 1509-1517
[2]
Colao A(1999)Epidemiology of acromegaly Pituitary 2 29-41
[3]
Barkan A(2017)Epidemiology of acromegaly: review of population studies Pituitary 20 4-9
[4]
Molitch M(2013)Epidemiology of acromegaly in Spain Endocrinol Nutr 60 470-474
[5]
Grossman AB(2014)Acromegaly: an endocrine society clinical practice guideline J Clin Endocrinol Metab 99 3933-3951
[6]
Kleinberg D(2017)Pegvisomant in acromegaly: an update J Endocrinol Invest 40 577-589
[7]
Holdaway IM(2001)Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist Lancet 358 1754-1759
[8]
Rajasoorya C(2000)Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant N Engl J Med 342 1171-1177
[9]
Lavrentaki A(2012)Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY J Clin Endocrinol Metab 97 1589-1597
[10]
Paluzzi A(2016)Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY Pituitary 19 127-137